Aspira Women's Health Inc. (AWH) |
|
3.27 -0.02 (-0.61%)
|
05-31 12:59 |
|
Open: |
3.29 |
Pre. Close: |
3.29 |
|
High:
|
3.29 |
Low:
|
3.11 |
|
Volume:
|
20,635 |
Market Cap:
|
27(M) |
|
|
|
Technical analysis |
as of: 2023-05-31 12:46:22 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 5.36 One year: 6.48 |
| Support: |
Support1: 3.04 Support2: 2.53 |
| Resistance: |
Resistance1: 4.59 Resistance2: 5.55 |
| Pivot: |
3.97  |
| Moving Average: |
MA(5): 3.59 MA(20): 4.16
MA(100): 6.04 MA(250): 7.33 |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 11.3 %D(3): 20.3 |
| RSI: |
RSI(14): 29.1 |
| 52-week: |
High: 16.5 Low: 3.04 |
| Average Vol(K): |
3-Month: 22 (K) 10-Days: 38 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AWH ] has closed below the lower bollinger band by 0.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 25.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.59 - 3.62 |
3.62 - 3.64 |
|
Low:
|
2.99 - 3.02 |
3.02 - 3.05 |
|
Close:
|
3.25 - 3.29 |
3.29 - 3.32 |
|
Company Description |
|
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas. |
Headline News |
Wed, 31 May 2023
Aspira Women's Health Announces the Publication of Three - GlobeNewswire
Tue, 30 May 2023
Aspira Women's Health to Participate at William Blair's - GlobeNewswire
Fri, 26 May 2023
New to The Street Announces the Televised Lineups for Shows 471, 472, and 473; Airings on Three Networks Will Begin on Saturday, May 27, 2023, at 3:30 PM ET - Yahoo Finance
Fri, 19 May 2023
New to The Street Announces its Televised Corporate Interviews Airing on Newsmax and The FOX Business Network, Episodes 469 and 470; Broadcastings Begin Saturday, May 20, 2023, at 3:30 PM ET - Yahoo Finance
Fri, 19 May 2023
New to The Street Announces its Televised Corporate Interviews ... - GlobeNewswire
Tue, 16 May 2023
Aspira Women’s Health Names Torsten Hombeck as Chief Financial Officer - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
8 (M) |
| Shares Float |
5 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
66 (K) |
|
Shares Short P.Month
|
77 (K) |
Stock Financials |
|
EPS
|
-2.91 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.1 |
|
Profit Margin (%)
|
-278.5 |
|
Operating Margin (%)
|
-340.3 |
|
Return on Assets (ttm)
|
-86.5 |
|
Return on Equity (ttm)
|
-212.4 |
|
Qtrly Rev. Growth
|
22.2 |
|
Gross Profit (p.s.)
|
0.51 |
|
Sales Per Share
|
1.03 |
|
EBITDA (p.s.)
|
-3.49 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-1.09 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
31.35 |
|
Price to Sales
|
3.03 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
